GS:"Investors shift from pessimism to skepticism, but risks remain that explain asymmetric return forec. Biotech M&amp;A: $BMY noted this week that its “very possible” that there now “more opportunities” available for BD, echoing similar appetite from others ( $PFE, $MRK, $Sanofi).."